



**Johann S de Bono**

**Kontakt**

Johann S de Bono

## Publikationen (21)

Hoyle A, Aebbersold D, Jones R, Matheson D, Millman R, Mason M, Ritchie A, Russell M, Douis H, Parmar M, Sydes M, Clarke N, Gillessen Sommer S, Ingleby F, Ali A, James N, Cook A, Parker C, de Bono J, Attard G, Chowdhury S, Cross W, Dearnaley D, Brawley C, Gilson C, STAMPEDE Investigators. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. *Eur Urol* 2019; 76:719-728.

Rescigno P, Romero-Laorden N, Castro E, Saez M, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu S, Sternberg C, De Giorgi U, Olmos D, Morley C, Pezaro C, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin A, Schmid S, Caffo O, Zivi A, de Bono J. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. *Eur Urol Oncol* 2019

Mateo J, Tomlins S, Tombal B, Sweeney C, Smith M, Shore N, Oyen W, Pérez-López R, Heidenreich A, Gillessen Sommer S, Fizazi K, de Bono J. Managing Nonmetastatic Castration-resistant Prostate Cancer. *Eur Urol* 2018

Sumanasuriya S, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein N, Terstappen L, Waugh D, Lorente D, Lolkema M, Omlin A, Armstrong A, Attard G, Chi K, Bevan C, Shibakawa A, IJerman M, De Laere B, de Bono J. Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. *Eur Urol Oncol* 2018; 1:151-159.

Gillessen Sommer S, de Bono J, Sartor O, Omlin A. Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2017.06.002>. *Eur Urol* 2017

STAMPEDE Investigators, McPhail N, McKinna F, Malik Z, Lester J, Hoskin P, Hingorani M, Gray E, Gale J, Ferguson C, Chakraborti P, Money-Kyrle J, O'Sullivan J, Sydes M, Parmar M, Zarkar A, Wylie J, Wagstaff J, Thomas C, Srihari N, Robinson A, Protheroe A, Parikh O, Brock S, Bowen J, Matheson D, Jones R, Gilson C, Amos C, Ritchie A, Dearnaley D, Mason M, Clarke N, Spears M, de Bono J, Millman R, Attard G, Birtle A, Aung S, Adab F, Brawley C, Berthold D, Russell J, Parker C, Gillessen Sommer S, Cross W, Chowdhury S, James N. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N Engl J Med* 2017; 377:338-351.

James N, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar M, Sydes M, Engeler D, Birtle A, Spears M, Clarke N, Dearnaley D, Mason M, Parker C, Ritchie A, Russell J, Schiavone F, Attard G, de Bono J. Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. *JAMA Oncol* 2016; 2:348-57.

Pérez-López R, Koh D, de Bono J, Leach M, Zivi A, Omlin A, Bianchini D, Mateo J, Collins D, Blackledge M, Lorente D, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. *Radiology* 2016; 280:151-60.

Omlin A, Sartor O, Rothermundt C, Cathomas R, de Bono J, Shen L, Su Z, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. *Clin Genitourin Cancer* 2015

Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. *Cancer* 2014; 120:3346-52.

Yap T, Lorente D, Omlin A, Olmos D, de Bono J. Circulating tumor cells: a multifunctional biomarker. *Clin Cancer Res* 2014; 20:2553-68.

Loriot Y, Ouatas T, Holtkamp G, Baron B, Heeringa M, Baskin-Bey E, James N, Omlin A, Molife R, Van den Brande J, Jones R, Fizazi K, de Bono J. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. *Invest New Drugs* 2014; 32:995-1004.

de Bono J, Scranton J, Wang T, Hudes G, Gillissen Sommer S, Fong P, Sandhu S, Aparicio L, Saad F, Petrylak D, Pandha H, Piulats J, Pollak M. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2014; 20:1925-34.

Molife L, Pelling K, Temple G, Heath C, Wheatley D, Oommen N, Thompson E, Jenkins P, Hickish T, Pedley I, O'Sullivan J, Olmos D, Fong P, Lumsden G, Bloomfield D, Karavasilis V, Jones R, Omlin A, de Bono J. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. *Future Oncol* 2014; 10:219-31.

Lorente D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Bianchini D, de Bono J. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. *Eur J Cancer* 2014; 50:1042-3.

Pezaro C, de Bono J, Parker C, Dearnaley D, Bianchini D, Ferraldeschi R, Lorente D, Altavilla A, Omlin A, Attard G. Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. *Eur Urol* 2013

Pezaro C, de Bono J, Tunariu N, Crespo M, Altavilla A, Riisnaes R, Mukherji D, Bianchini D, Ferraldeschi R, Nava Rodrigues D, Lorente D, Omlin A, Attard G. Visceral Disease in Castration-resistant Prostate Cancer. *Eur Urol* 2013; 65:270-3.

Sandhu S, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter C, Iannone R, Kaye S, de Bono J, Thway K, Kreischer N, Schelman W, Wilding G, Moreno V, Baird R, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Wenham R. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncol* 2013; 14:882-92.

Yap T, Omlin A, de Bono J. Development of therapeutic combinations targeting major cancer signaling pathways. *J Clin Oncol* 2013; 31:1592-605.

Omlin A, de Bono J. Therapeutic options for advanced prostate cancer: 2011 update. *Curr Urol Rep* 2012; 13:170-8.

Yap T, Zivi A, Omlin A, de Bono J. The changing therapeutic landscape of castration-resistant prostate cancer. *Nat Rev Clin Oncol* 2011; 8:597-610.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)